Related Experiment Video
Updated: May 23, 2026

Single-stage Dynamic Reanimation of the Smile in Irreversible Facial Paralysis by Free Functional Muscle Transfer
Published on: March 1, 2015
No effect of corticosteroid treatment for idiopathic facial paralysis
Kristian Friesgaard Christensen1, Therese Ovesen, Christer Swan Andreassen
1Department of Otorhinolaryngology, Head and Neck Surgery, Aarhus University Hospital, Aarhus, Denmark. christer.andreassen@ki.au.dk
Introduction:
This retrospective cohort study aimed to determine if the effect of corticosteroid treatment on idiopathic facial palsy (IFP) could be reproduced in patients treated in a strictly clinical setting.
Material And Methods:
A total of 43 patients diagnosed with IFP in the period 2004-2009 were included and patient files were reviewed. Treatment with corticosteroids was introduced as standard treatment for this disease in December 2006, ensuring groups of similar size. In all, 20 patients had received prednisolone and 23 patients had not. Baseline characteristics were registered and severity of facial palsy according to the House-Brackmann grading system (HB) was determined before treatment and at follow-up.
Results:
Change in HB score did not differ between participant groups (delta HB: 3 (range: 0-5), and 3 (range: 1-5), patients treated with steroids versus patients receiving no treatment, respectively, p = 0.69). When dividing patients into sub-groups according to age (age >/≤ 40 years), no difference was found for change in HB score between treatment groups for either age group (age ≤ 40 years; p = 0.59, and age > 40 years; p = 0.12). The effect of steroid treatment on outcome was larger among older than among younger patients (p = 0.03).
Conclusion:
Treatment with prednisolone does not improve short-term outcome in patients with IFP in an unselected clinical setting. Further studies should evaluate the possible effect of age on treatment outcome.
Funding:
not relevant.
Trial Registration:
not relevant.
Related Concept Videos
Skeletal Muscle Relaxants: Adverse Effects
Unlike...
Classification of Skeletal Muscle Relaxants
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
The binding of dantrolene to the RYR1...
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
Although all competitive neuromuscular blockers are designed...
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
